Three Months Ended June 30, 2026

Gyre Pharmaceuticals

Gyre

Total

Revenues

$

29,097

$

8

$

29,105

Operating expenses

Cost of revenues

2,209

—

2,209

Selling and marketing

13,754

—

13,754

Research and development

9,697

4,603

14,300

Research and development - related parties

4,836

—

4,836

General and administrative

4,268

3,594

7,862

Transaction costs

—

502

502

Total segment operating expenses

34,764

8,699

43,463

Loss from segment operations

(5,667

)

(8,691

)

(14,358

)

Other segment (loss) income, net:

Interest income

252

488

740

Other expense, net

(391

)

(552

)

(943

)

Change in fair value of warrant liability

—

132

132

Benefit (provision) for income taxes

165

(1

)

164

Net segment (loss) income

$

(5,641

)

$

(8,624

)

$

(14,265

)

Reconciliation of profit or loss

Other general and administrative expenses

5

Total Consolidated net loss

$

(14,270

)

Supplemental disclosure of stock-based compensation expense:

Cost of revenue

$

122

$

—

$

122

Selling and marketing

661

—

661

Research and development

79

—

79

General and administrative

344

627

971

Stock-based compensation total

$

1,206

$

627

$

1,833

Six Months Ended June 30, 2026

Gyre Pharmaceuticals

Gyre

Total

Revenues

$

51,616

$

1,919

$

53,535

Operating expenses

Cost of revenues

3,436

—

3,436

Selling and marketing

27,890

—

27,890

Research and development

15,163

10,618

25,781

Research and development - related parties

4,836

—

4,836

General and administrative

9,025

9,007

18,032

Transaction costs

—

6,886

6,886

Total segment operating expenses

60,350

26,511

86,861

Loss from segment operations

(8,734

)

(24,592

)

(33,326

)

Other segment (loss) income, net:

Interest income

517

966

1,483

Other expense, net

(818

)

(12

)

(830

)

Change in fair value of warrant liability

—

220

220

Benefit (provision) for income taxes

(456

)

71

(385

)

Net segment loss

$

(9,491

)

$

(23,347

)

$

(32,838

)

Reconciliation of profit or loss

Other general and administrative expenses

11

Consolidated net loss

$

(32,849

)

Supplemental disclosure of stock-based compensation expense:

Cost of revenue

$

300

$

—

$

300

Selling and marketing

1,646

—

1,646

Research and development

194

—

194

General and administrative

779

1,739

2,518

Stock-based compensation total

$

2,919

$

1,739

$

4,658

Three Months Ended June 30, 2025 (As Recast)

Gyre Pharmaceuticals

Gyre

Total

Revenues

$

26,771

$

2,963

$

29,734

Operating expenses:

Cost of revenues

1,151

—

1,151

Selling and marketing

15,195

—

15,195

Research and development

3,337

5,014

8,351

General and administrative

2,858

4,417

7,275

Total segment operating expenses

22,541

9,431

31,972

Income (loss) from segment operations

4,230

(6,468

)

(2,238

)

Other segment (loss) income, net:

Interest income

271

670

941

Other (expense) income, net

(507

)

19

(488

)

Change in fair value of warrant liability

-

212

212

Provision for income taxes

(662

)

-

(662

)

Net segment income (loss)

$

3,332

$

(5,567

)

$

(2,235

)

Reconciliation of profit or loss

Other general and administrative expenses

2

Total Consolidated net loss

$

(2,237

)

Supplemental disclosure of stock-based compensation expense:

Cost of revenue

$

47

$

—

$

47

Selling and marketing

29

—

29

General and administrative

273

709

982

Research and development

—

62

62

Stock-based compensation total

$

349

$

771

$

1,120

Six Months Ended June 30, 2025 (As Recast)

Gyre Pharmaceuticals

Gyre

Total

Revenues

$

48,829

$

11,476

$

60,305

Operating expenses:

Cost of revenues

2,045

—

2,045

Selling and marketing

26,035

—

26,035

Research and development

6,366

10,076

16,442

General and administrative

6,414

9,062

15,476

Total segment operating expenses

40,860

19,138

59,998

Income (loss) from segment operations

7,969

(7,662

)

307

Other segment (loss) income, net:

Interest income

555

1,242

1,797

Other (expense) income, net

(729

)

428

(301

)

Change in fair value of warrant liability

—

2,467

2,467

Provision for income taxes

(1,563

)

—

(1,563

)

Net segment income (loss)

$

6,232

$

(3,525

)

$

2,707

Reconciliation of profit or loss

Other general and administrative expenses

5

Total Consolidated net loss

$

2,702

Supplemental disclosure of stock-based compensation expense:

Cost of revenue

$

47

$

—

$

47

Selling and marketing

29

—

29

General and administrative

351

1,373

1,724

Research and development

—

143

143

Stock-based compensation total

$

427

$

1,516

$

1,943

June 30, 2026

Gyre Pharmaceuticals

Gyre

Other Unallocated Amount

Consolidated

Total assets

$

139,241

$

59,657

$

357

$

199,255

December 31, 2025 (As Recast)

Gyre Pharmaceuticals

Gyre

Other Unallocated Amount

Consolidated

Total assets

$

138,407

$

81,000

$

356

$

219,763

Six Months Ended June 30, 2026

Gyre Pharmaceuticals

Gyre

Other Unallocated Amount

Consolidated

Purchase of property and equipment

$

386

$

54

$

—

$

440

Six Months Ended June 30, 2025 (As Recast)

Gyre Pharmaceuticals

Gyre

Other Unallocated Amount

Consolidated

Purchase of property and equipment

$

378

$

79

$

—

$

457